WCIO-1: Philosophy of Immuno-Oncology
For this session, the topics include but not limited to the following:
1. New Concepts in Cancer Immunology, Tumor Microenvironmental Perspective and Immunotherapy
2. Which Ways to Go for Immuno-Oncology
3. Drugging the 'Undruggable' Targets in Cancer Immunotherapy
4. Toward Precision Immuno-Oncology

WCIO-2: Global Immuno-Oncology Landscape Analysis Update
For this session, the topics include but not limited to the following:
1. Outlook of Global Immuno-Oncology Landscape
2. Current Progress on Dynamic Target Clusters
3. Small Molecules Maximally Optimizing Immuno-Oncology Therapies
4. What's Next for Immune Checkpoint Blockade
5. Updates on Cancer Immunotherapy in China
6. Comprehensive Review of the Clinical Immuno-Oncology

WCIO-3: Emerging IO Biomarkers and Targets
For this session, the topics include but not limited to the following:
1. The Current Biomarker Roadmap in Immuno-Oncology
2. Landscape of Predictive IO Biomarkers and Companion Diagnostics
3. New Immuno-Oncology Biomarkers Discovery
4. How to Make IO Biomarker Reproducible for Tran
slational Medicine
5. Novel Neoantigens as Emerging IO Targets
6. Targeting Granulocyte-Macrophage CSF or GM-CSF/GM-CSFR
7. Targeting TGF-β, LAG3, TIM3 and GPC3
8. Nich Targets from Popular Ones

WCIO-4: Adoptive Cell Therapy
For this session, the topics include but not limited to the following:
1. New Strategy of Reprogramming Regulatory T Cells
2. Emerging Universal CAR T-Cells Targeting Solid Tumors
3. Gene/Genome Editing for Adoptive Cell Therapies
4. Hot Targeted Antigens for Cell Therapy

WCIO-5: Customized Cancer Vaccines
For this session, the topics include but not limited to the following:
1. New Paradigm for Developing Precision Vaccines
2. Personalized and Customized Cancer Vaccines
3. Smart Personalized Cancer Vaccine Adjuvants and Formulation
4. mRNA and Individualized Neoantigen Specific Cancer Vaccines

WCIO-6: Disruptive OI Technologies
For this session, the topics include but not limited to the following:
1. Disruptive Biotech in Discovering Neoantigens and Immunotherapy Modalities
2. Gene editing/ Genome Editing and T-cell Immune-Editing Strategies
3. Smart Technologies in IO
4. IO Nanomedicine
5. Bioanalysis in IO

WCIO-7: Rational Combinational Cancer Immunotherapy
For this session, the topics include but not limited to the following:
1. Preclinical Modeling for the Cancer Combination Immunotherapy
2. Patient Safety, Toxicity Profiles in Combinatorial IO
3. Clinical Trial Design, and Endpoints of IO Combination Therapy
4. Successful Case Studies on Combinatorial Cancer Immunotherapy

WCIO-8: Immunomodulatory Proteins and Polysaccharides
For this session, the topics include but not limited to the following:
1. Immunomodulator Targets under Clinical Trial
2. Immunomodulatory Therapeutic Antibodies
3. Cytokines as IO Immunomodulators
4. Polysaccharides and Polysaccharide-Proteins in IO

WCIO-9: Translational Immuno-Oncology and Clinical Practices
For this session, the topics include but not limited to the following:
1. Enabled Translational Platform for Immuno-Oncology
2. Clinical Trials in the Era of AI and Big Data
3. Clinical Trials Strategy and Practices for IO
4. Toxicity and Side Effects Management of Cancer Immunotherapy

WCIO-10: Oncolytic Virus Immuno-Oncology
For this session, the topics include but not limited to the following:
1. Future of Oncolytic Virus Immunotherapy
2. Optimizing Viral Vectors for Direct Manipulation of the Adaptive Immune System
3. Oncolytic Virus based Combination IO
4. OVs Biosimilars and Biobetters